Literature DB >> 10708005

High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis.

S Gasim1, T G Theander, A M ElHassan.   

Abstract

Post kala-azar dermal leishmaniasis (PKDL) is a known sequel to visceral leishmaniasis in India and East Africa, and in Sudan about 50% of the kala-azar patients develop PKDL. In this study we followed kala-azar patients from diagnosis and up to 2 years after initiation of treatment. During the first 6 months some developed PKDL (group 1), while some did not develop PKDL (group 2). We measured the plasma levels of C-reactive protein (CRP) at diagnosis of kala-azar (day 0), during treatment (day 15), after treatment (day 30) and later during the follow up period. At day 0, plasma CRP levels were higher in patients who later developed PKDL (group 1) than in patients who did not develop PKDL subsequently (group 2) (P = 0.008). At days 15 and 30, the CRP levels were comparable in the two groups, and lower than at day 0. We have previously shown that high plasma levels of IL 10 and in keratinocytes during visceral leishmaniasis predict subsequent development of PKDL. The method however requires expensive equipment and reagents. The results of the present study indicate that kala-azar patients, who have a high risk of developing PKDL after treatment can be identified by measuring plasma CRP.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708005     DOI: 10.1016/s0001-706x(99)00089-3

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  7 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

Review 2.  C-reactive protein and the biology of disease.

Authors:  Waliza Ansar; Shyamasree Ghosh
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 3.  Post kala-azar dermal leishmaniasis: an unresolved mystery.

Authors:  Debanjan Mukhopadhyay; Jane E Dalton; Paul M Kaye; Mitali Chatterjee
Journal:  Trends Parasitol       Date:  2014-01-02

Review 4.  Post kala-azar dermal leishmaniasis: A threat to elimination program.

Authors:  Mallikarjuna Rao Gedda; Bhawana Singh; Dhiraj Kumar; Abhishek Kumar Singh; Prasoon Madhukar; Shreya Upadhyay; Om Prakash Singh; Shyam Sundar
Journal:  PLoS Negl Trop Dis       Date:  2020-07-02

5.  Epidemiology of Post-Kala-azar Dermal Leishmaniasis.

Authors:  Pramit Ghosh; Pritam Roy; Surya Jyati Chaudhuri; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

6.  Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.

Authors:  Eltahir Awad Gasim Khalil; Selma Abdelmoneim Khidir; Ahmed Mudawi Musa; Brema Younis Musa; Mona Elfaki Eltahir Elfaki; Abdelgadir Mohamed Yousif Elkadaru; Edward Zijlstra; Ahmed Mohamed El-Hassan
Journal:  J Trop Med       Date:  2013-03-24

Review 7.  Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.

Authors:  Maria Angela Bianconcini Trindade; Lana Luiza da Cruz Silva; Lucia Maria Almeida Braz; Valdir Sabbaga Amato; Bernard Naafs; Mirian Nacagami Sotto
Journal:  BMC Infect Dis       Date:  2015-11-23       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.